Asian patient groups have an above average impression of pharmaceutical companies, according to a new report.
New data from PatientView’s established corporate reputation survey show 49% of patient groups in Asia believe the sector has an ‘excellent’ or ‘good’ corporate reputation.
The figures, drawn from 98 patient groups from Australasia, Central Asia, East Asia, South Asia and South-East Asia, present a rosier picture than their counterparts from around the world, 37% of which held the same view.
PatientView’s 2016 Corporate Reputation of Pharma Companies survey covers the efforts of 16 global pharma companies including Pfizer – which was ranked the most familiar to the Asian patient groups.
Respondents also ranked AbbVie as overall first for corporate reputation among the groups familiar with the firm. The US company ranked first for patient-centricity, transparency and patient-group relations as well.
Meanwhile, GSK was placed first for the provision of ‘high-quality’ patient information and Novo Nordisk took first position for patient safety, high quality products and integrity.